BIOCON LTD. - 532523 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome/Proceedings of AGM held on July 28, 202229-07-2022
29-07-2022
We're geared to launch a new molecule every 1-2 years: Biocon Biologics MD
In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda29-07-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor meet28-07-2022
BIOCON LTD. - 532523 - Presentation And Video Recording Of Q1FY23 Earnings Call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), please find enclosed the presentation on Q1FY23 Earnings Call conducted today i.e. on July 28, 2022. The same is also available on the website of the Company at www.biocon.com. Further, the Video Recording w.r.t. the Earnings Call is also available on the website of the Company at https://www.biocon.com/investor-relations/financial-information/quarterly-reports/fy-2022-23/.28-07-2022
Results Earnings Call for Q1FY23 of Biocon Ltd.
Conference Call with Biocon Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: MD Kiran Mazumdar Shaw and Senior Team28-07-2022
Q1FY23 Quarterly Result Announced for Biocon Ltd.
Biotechnology firm Biocon Announced Q1FY23 Result : Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25% Biosimilars Up 29%; Generics Up 19%; Research Services Up 8% “We have had a strong start to the year. At a consolidated level, YoY revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics (19%). Core EBITDA grew 25% and margin improved to 31% compared to 30% in Q1FY22. and Net Profit grew 71% to Rs 144 Crore. Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains. R&D; investments increased significantly by Rs 87 Crore this quarter reflecting pipeline progression to deliver future growth. All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the COVID-19 pandemic.” -- Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics. Result PDF28-07-2022
Biocon'sQ1 net profit up by 71 per cent to 144crore
Biocon's biosimilars segment contributed the most revenue at 977 crore27-07-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
With reference to the captioned subject, please find enclosed the Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). The above information will also be available on the website of the Company at https://www.biocon.com.27-07-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%'.27-07-2022